Parkinson’s Disease
Is Angiogenesis a Treatment or Potential Cure?
Zhittya Genesis Medicine is developing a drug, fibroblast growth factor 1 (FGF-1), to possible treat Parkinson's Disease by growing new blood vessels in ischemic tissue in the brain, particularly by reestablishing blood flow in dopamine-producing parts of the brain such as the substantia nigra.
As of May 2022, Zhittya Genesis Medicine has dosed over 150 individuals suffering from Parkinson's Disease in Medical Research Studies. Beyond demonstrating potentially impressive safety data, it has also reported improved motor scores of all Parkinson's patients in the study. Beyond improved motor scores, patients have reported non-motor improvements such as improvements in sleep quality, balance, cognition, among other qualities.
Our Data: Graphed
MDS-UPDRS Score v. Month
History
FGF-1 is a potent stimulator of angiogenesis, the growth of new blood vessels, and is capable of growing new blood vessels in ischemic areas of the body, including the brain. Research has indicated that a lack of blood perfusion to dopamine producing neurons located in the substantia nigra region of the brain lead to a lack of dopamine and the classic symptoms of Parkinson’s Disease.
In the past, FGF-1 has been able to grow new blood vessels in the human body. In a US FDA Phase IIA clinical trial, conducted at the University of Cincinnati, our drug was able to grow new blood vessels in the hearts of individuals with coronary artery disease, improving many of their symptoms.
FGF-1 has also shown excellent efficacy in treating Parkinson’s Disease in Cynomolgus monkey models. After being injected with a neurotoxin that selectively destroys dopamine-producing neurons, the two groups of monkeys came down with the classic symptoms of Parkinson’s Disease. One group was a placebo group and another was administered FGF-1, which lead to improvement in motor scores, increased dopamine production, and decreased plaque build-up.
Watch as Zhittya Genesis Medicine’s drug is used to grow new blood vessels in the human heart in a US FDA Phase IIA Clinical Trial done at the University of Cincinnati, and reported by ABC Nightly News. Zhittya believes that by growing new blood vessels in the human brain, that the symptoms of Parkinson’s Disease can be alleviated.
Watch our theory of how we believe FGF-1 can be used to treat Parkinson’s Disease by growing new blood vessels in this animated video which shows our theory of our blood vessels grow, reestablish blood flow to dopamine producing regions of the brain, thereby increasing dopamine production in the brain, and relieving the symptoms of Parkinson’s Disease.
Our Partners
-
![]()
University of Nevada, Reno
Zhittya Genesis Medicine continues to cooperate and work with research and laboratory staff at the University of Nevada, Reno where Zhittya conducts some of its research related to FGF-1, Parkinson’s Disease, and more.
-
![]()
Cross Border Medical Tourism
Zhittya Genesis Medicine’s partner in patient facilitation, patient logistics, and operations based in Los Angeles, California. Cross Border Medical Tourism ensures that all of our patients are cared for throughout our programs.
-
![]()
WundHealing Biopharmaceuticals
Zhittya Genesis Medicine’s marketing partner based in Las Vegas, Nevada, helping Zhittya Genesis Medicine market and distribute our potential treatment following anticipated approval by the US FDA and other regulatory bodies.
News
-
![]()
January 2024 Update
Zhittya Genesis Medicine’s January 2024 update provides an insightful overview of their ongoing efforts and groundbreaking research in 2024. The company is making strides in treating Parkinson's disease especially as they work to develop strategic collaborations with renowned medical imaging centers in the United States and Italy. These partnerships aim to scientifically demonstrate how FGF-1 enhances brain blood flow and potentially reverses disease symptoms.
-
![]()
February 2024 Update
Zhittya Genesis Medicine’s February 2024 update details the company's busy start to the year, with significant developments in their research and treatment offerings, particularly focusing on FGF-1's potential in addressing various diseases. Zhittya recounts successful presentations and interactions at the Dubai Cardiovascular Conference, emphasizing the international medical community's growing interest in FGF-1 for treating small vessel heart disease, Parkinson’s disease, and other neurodegenerative conditions. Additionally, it highlights the progress in brain scanning and blood flow imaging studies, aiming to empirically demonstrate FGF-1's effectiveness in improving cerebral blood perfusion.
-
![]()
Zhittya finishes additional production of FGF-1
February 2024:
Zhittya Genesis Medicine completes the production of additional FGF-1 with its partners. This new batch of FGF-1 will allow for Zhittya Genesis Medicine to continue to conduct studies into the future for Parkinson’s Disease.
-
![]()
March 2024 Update
Zhittya Genesis Medicine’s March 2024 update discusses their recent activities, particularly focusing on the treatment of Parkinson's disease patients with FGF-1 through their ongoing medical research studies. The company's ongoing research is exploring how continual dosing with FGF-1 can aid in the recovery and improvement of patients' conditions. Despite the uncertainties and the complex journey of discovery, positive changes in patients have been observed, leading to renewed hope and potential treatment strategies. Additionally, the update delves into the intriguing aspect of where the administered FGF-1 goes within the brain, considering the vast number of molecules unaccounted for and the possible extensive repair work being undertaken within the brain's complex structure.
-
![]()
Zhittya Doses 150th Patient
April 2024:
Zhittya Genesis Medicine is proud to announce that they have dosed their 150th Parkinson’s Disease patient in their medical research studies, proving as a substantial milestone for Zhittya’s potential treatment. With 150 patients now dosed, Zhittya has seen no reported adverse events and a 53% improvement, on average, in reported motor scores. -
![]()
April 2024 Update
This update from Zhittya Genesis Medicine, dated April 2024, highlights their continued efforts in advancing treatments for Parkinson’s disease and other health conditions using FGF-1. The company celebrates treating over 150 Parkinson's disease sufferers with notable improvements and minimal side effects. As the two-year mark approaches since the first human dosing, they are beginning to gather long-term efficacy data. Furthermore, the update contrasts FGF-1 treatment with deep brain stimulation (DBS), emphasizing FGF-1's non-invasive application and broader health benefits over the surgical and potentially riskier DBS.
-
![]()
May 2024 Update
Zhittya Genesis Medicine’s latest update provides an insightful overview of their ongoing efforts and groundbreaking research in 2024. The company has achieved significant milestones, including the first brain scan measuring blood perfusion in a Parkinson’s patient and a successful spinal tap delivery of FGF-1. Their recent conference in The Bahamas highlighted potential treatments for Parkinson’s and coronary heart disease, and they are planning new applications for critical leg ischemia and diabetic foot ulcers. Celebrating two years of treating Parkinson's patients, Zhittya has treated over 150 subjects and continues to work with US agencies to seek approval for their innovative treatments.
-
![]()
2 Years of Parkinson's Disease Studies
May 2024:
Zhittya Genesis Medicine celebrates its second year of conducting Parkinson’s Disease medical research studies, which has treated over 150 individuals suffering from Parkinson’s Disease.
